Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results through Week 48 from the phase 3 GRAVITI study

被引：0

作者：

Hart, A. ^{[1
]}

Panaccione, R. ^{[2
]}

Steinwurz, F. ^{[3
]}

Danese, S. ^{[4
,5
]}

Hisamatsu, T. ^{[6
]}

Cao, Q. ^{[7
]}

Olurinde, M. ^{[8
]}

Vetter, M. L. ^{[8
]}

Yang, Z. ^{[8
]}

Wang, Y. ^{[8
]}

Johanns, J. ^{[8
]}

Terry, N. A. ^{[8
]}

Sands, B. E. ^{[9
]}

D'Haens, G. ^{[10
]}

机构：

[1] London North West Univ Healthcare NHS Trust, Gastroenterol, London, England

[2] Univ Calgary, Gastroenterol, Calgary, AB, Canada

[3] Hosp Israelita Albert Einstein, Gastroenterol, Sao Paulo, Brazil

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Univ Vita Salute San Raffaele, Gastroenterol, Milan, Italy

[6] Kyorin Univ, Dept Pathol, Tokyo, Japan

[7] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Gastroenterol, Hangzhou, Peoples R China

[8] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[9] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA

[10] Univ Amsterdam, Gastroenterol, Med Ctr, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0033

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP33

引用

页码：i66 / i67

页数：2

共 50 条

[1] Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
Panaccione, Remo
Hart, Ailsa
Steinwurz, Flavio
Danese, Silvio
Hisamatsu, Tadakazu
Cao, Qian
Olurinde, Mobolaji
Vetter, Marion
Yang, Zijiang
Wang, Yuhua
Johanns, Jewel
Terry, Natalie A.
Sands, Bruce E.
D'Haens, Geert R.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S740 - S741
[2] Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results at Week 12 from the phase 3 GRAVITI study
D'Haens, G.
Hisamatsu, T.
Steinwurz, F.
Hart, A.
Liu, W.
Olurinde, M.
Ngqawa, P.
Yang, Z.
Merrall, E.
Terry, N. A.
Sands, B. E.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1608 - I1609
[3] Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn's disease: Phase 3 GRAVITI study results through week 48
Hart, A.
Panaccione, R.
Steinwurz, F.
Cao, Q.
Hisamatsu, T.
Nancey, S.
Olurinde, M.
Yang, Z.
Merrall, E.
Terry, N. A.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1662 - i1663
[4] Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn's disease: Results from the phase 3 GRAVITI study
Hart, A.
Hisamatsu, T.
Steinwurz, F.
D'Haens, G.
Liu, W.
Olurinde, M.
Ngqawa, P.
Yang, Z.
Merrall, E.
Terry, N. A.
Panaccione, R.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1312 - i1314
[5] Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: Subgroup analysis of the Phase 3 GRAVITI study
Liu, W.
Guo, H.
Kim, T. O.
Takeuchi, K.
Hisamatsu, T.
Fable, J.
Olurinde, M.
Wahking, B.
Zhuo, J.
Cao, Q.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1899 - I1901
[6] EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
Panaccione, Remo
Rubin, David T.
Sands, Bruce E.
Reinisch, Walter
D'Haens, Geert
Panes, Julian
Gonzalez, Susana
Weisel, Kathleen
Sahoo, Aparna
Frustaci, Mary Ellen S.
Yang, Zijiang
Sandborn, William J.
Afzali, Anita
Hisamatsu, Tadakazu
Danese, Silvio
Andrews, Jane M.
Feagan, Brian G.
GASTROENTEROLOGY, 2022, 162 (07) : S216 - S217
[7] Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study
Danese, S.
Panaccione, R.
Rubin, D. T.
Sands, B. E.
Reinisch, W.
D'Haens, G.
Panes, J.
Gonzalez, S.
Weisel, K.
Sahoo, A.
Frustaci, M. E.
Yang, Z.
Sandborn, W. J.
Afzali, A.
Hisamatsu, T.
Andrews, J. M.
Feagan, B.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I026 - I027
[8] Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study
Danese, Silvio
Panaccione, Remo
Rubin, David T.
Sands, Bruce E.
Reinisch, Walter
D'Haens, Geert
Panes, Julian
Gonzalez, Susana
Weisel, Kathleen
Sahoo, Aparna
Frustaci, Mary Ellen
Yang, Zijiang
Sandborn, William J.
Afzali, Anita
Hisamatsu, Tadakazu
Andrews, Jane M.
Feagan, Brian G.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3656 - 3660
[9] EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
Panaccione, Remo
Danese, Silvio
Feagan, Brian G.
D'Haens, Geert
Afzali, Anita
Reinisch, Walter
Panes, Julian
Rubin, David T.
Andrews, Jane M.
Hisamatsu, Tadakazu
Terry, Natalie A.
Salese, Leonardo
Van Rampelbergh, Rian
Frustaci, Mary Ellen S.
Yang, Zijiang
Johanns, Jewel
Wan, Kitty Y.
Yee, Jacqueline
Sands, Bruce E.
GASTROENTEROLOGY, 2024, 166 (05)
[10] Efficacy And Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results of the Galaxi 2 & 3 Phase 3 Studies
Panaccione, Remo
Danese, Silvio
Feagan, Brian G.
D'Haens, Geert
Afzali, Anita
Reinisch, Walter
Panes, Julian
Rubin, David T.
Andrews, Jane
Hisamatsu, Tadakazu
Terry, Natalie A.
Salese, Leonardo
Van Rampelbergh, Rian
Frustaci, Mary Ellen
Yang, Zijiang
Johanns, Jewel
Wan, Kitty Yuen Yi
Yee, Jacqueline
Sands, Bruce E.
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2312 - 2318

← 1 2 3 4 5 →